Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA.
BMC Cancer. 2011 Jan 25;11:32. doi: 10.1186/1471-2407-11-32.
Retinoid receptor-induced gene-1 (RRIG1) is a novel gene that has been lost in several types of human cancers. The aim of this study was to determine whether RRIG1 plays a role in breast cancer, such as in the suppression of breast cancer cell growth and invasion.
Immunohistochemistry was used to detect RRIG1 expression in breast tissue specimens. Gene transfection was used to restore or knock down RRIG1 expression in breast cancer cell lines for analysis of cell viability, colony formation, and migration/invasion potential. Reverse-transcription polymerase chain reaction and western blot assays were used to detect the changes in gene expression. The RhoA activation assay was used to assess RRIG1-induced inhibition of RhoA activity.
The immunohistochemical data showed that RRIG1 expression was reduced in breast cancer tissues compared with normal and atypical hyperplastic breast tissues. RRIG1 expression was inversely correlated with lymph node metastasis of breast cancer but was not associated with the status of hormone receptors, such as estrogen receptor, progesterone receptor, or HER2. Furthermore, restoration of RRIG1 expression inhibited proliferation, colony formation, migration, and invasion of breast cancer cells. Expression of RRIG1 also reduced phosphorylated Erk1/2 and Akt levels; c-Jun, MMP9, and Akt expressions; and RhoA activity. In contrast, knockdown of RRIG1 expression promoted breast cancer cell proliferation, colony formation, migration, and invasion potential.
The data from the current study indicated that RRIG1 expression was reduced or lost in breast cancer and that restoration of RRIG1 expression suppressed breast cancer cell growth and invasion capacity. Future studies will determine the underlying molecular mechanisms and define RRIG1 as a tumor-suppressor gene in breast cancer.
维甲酸受体诱导基因-1(RRIG1)是一种新型基因,在几种人类癌症中丢失。本研究旨在确定 RRIG1 是否在乳腺癌中发挥作用,例如抑制乳腺癌细胞生长和侵袭。
采用免疫组织化学法检测乳腺癌组织标本中 RRIG1 的表达。采用基因转染技术恢复或敲低乳腺癌细胞系中 RRIG1 的表达,分析细胞活力、集落形成和迁移/侵袭潜能。采用逆转录聚合酶链反应和 Western blot 检测基因表达变化。采用 RhoA 激活测定法评估 RRIG1 诱导的 RhoA 活性抑制作用。
免疫组化数据显示,RRIG1 在乳腺癌组织中的表达低于正常和非典型增生性乳腺组织。RRIG1 的表达与乳腺癌的淋巴结转移呈负相关,但与激素受体(如雌激素受体、孕激素受体或 HER2)的状态无关。此外,恢复 RRIG1 的表达抑制了乳腺癌细胞的增殖、集落形成、迁移和侵袭。RRIG1 的表达还降低了磷酸化 Erk1/2 和 Akt 水平、c-Jun、MMP9 和 Akt 的表达以及 RhoA 活性。相反,敲低 RRIG1 的表达促进了乳腺癌细胞的增殖、集落形成、迁移和侵袭潜能。
本研究数据表明,RRIG1 在乳腺癌中表达降低或缺失,恢复 RRIG1 的表达抑制了乳腺癌细胞的生长和侵袭能力。未来的研究将确定潜在的分子机制,并将 RRIG1 定义为乳腺癌中的肿瘤抑制基因。